Open access
Aug 2026
Comparison of Patiromer and Sodium Polystyrene Sulfonate for Chronic Hyperkalemia in Patients with Chronic Kidney Disease: A Prospective Cohort Study
While both agents showed comparable potassium-lowering efficacy, patiromer's numerical advantages in tolerability and significant benefit in maintaining RAASi therapy position it as a valuable therapeutic option in this high-risk population.
Mashael Alzahrani, Douaa Sindi, Saeed M. G. Al-Ghamdi et al.
· Kidney Diseases · 0 citations